Compare PBYI & FT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PBYI | FT |
|---|---|---|
| Founded | 2010 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 263.4M | 201.6M |
| IPO Year | N/A | N/A |
| Metric | PBYI | FT |
|---|---|---|
| Price | $5.78 | $8.00 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | ★ 377.7K | 63.0K |
| Earning Date | 11-06-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.85% |
| EPS Growth | ★ 59.87 | N/A |
| EPS | ★ 0.74 | N/A |
| Revenue | ★ $211,995,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $7.75 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.58 | $5.97 |
| 52 Week High | $6.27 | $7.23 |
| Indicator | PBYI | FT |
|---|---|---|
| Relative Strength Index (RSI) | 54.93 | 53.07 |
| Support Level | $5.81 | $7.87 |
| Resistance Level | $6.27 | $8.07 |
| Average True Range (ATR) | 0.24 | 0.08 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 37.97 | 75.00 |
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
Franklin Universal Trust is a closed-end management investment company focused on providing high current income while preserving capital. Its secondary objective is to achieve income growth through dividend increases and capital appreciation. The fund invests in two asset classes: high-yield bonds and utility stocks. It applies fundamental research to build a diversified high-yield bond portfolio and targets utility companies with attractive dividend yields and a history of increasing dividends.